Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine (IMBCAMS)
- Development stage
- Unknown
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
A live-attenuated, bivalent oral poliovirus vaccine (bOPV) containing Sabin strains of poliovirus types 1 and 3. Developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS), this vaccine is designed to provide protection against poliomyelitis by inducing both systemic and intestinal mucosal immunity. It is available in both liquid and dragee candy formulations. The vaccine was developed as part of the global effort to switch from trivalent OPV (tOPV) to bOPV following the eradication of wild poliovirus type 2. Clinical studies have evaluated its long-term immunity duration and effectiveness when used in various sequential immunization schedules, including co-administration with inactivated poliovirus vaccine (IPV) boosters.
- Other names
- bivalent oral poliomyelitis vaccineSabin strain bivalent oral poliovirus vaccinebOPV (candy)bOPV (liquid)
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine (IMBCAMS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine (IMBCAMS).